Metformine Viatris (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial complex I, which reduces the liver’s production of glucose. It also activates AMP‑activated protein kinase (AMPK), leading to increased glucose uptake by muscle and fat cells and improved insulin sensitivity, without stimulating insulin release from the pancreas.

The dosage of Metformine Viatris is individualized by a prescriber based on the patient’s clinical condition, renal function, and response to therapy. Healthcare professionals determine the appropriate strength, frequency, and titration schedule to achieve optimal glycemic control.

Safety of metformin during pregnancy or lactation should be evaluated by a qualified healthcare provider. While some guidelines allow limited use when benefits outweigh risks, the decision must be individualized, and patients should discuss potential effects with their obstetrician or physician.

To request Metformine Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformine Viatris belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or insulin. It does not stimulate insulin secretion, carries a low risk of hypoglycemia when used alone, and offers weight‑neutral or modest weight‑loss benefits, making it a first‑line option for many patients with type 2 diabetes.

Metformine Viatris should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Metformine Viatris is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not crush or split extended‑release formulations unless instructed.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or unexplained fatigue develop.

Metformine Viatris is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with known hypersensitivity to metformin or any component of the formulation.